Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 30 (7), 679-92

Combinatorial Drug Therapy for Cancer in the Post-Genomic Era

Affiliations
Review

Combinatorial Drug Therapy for Cancer in the Post-Genomic Era

Bissan Al-Lazikani et al. Nat Biotechnol.

Abstract

Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.

Similar articles

See all similar articles

Cited by 243 articles

See all "Cited by" articles

References

    1. Cell. 2012 Mar 16;148(6):1099-109 - PubMed
    1. Nucleic Acids Res. 2011 Jan;39(Database issue):D691-7 - PubMed
    1. Science. 2004 Oct 22;306(5696):640-3 - PubMed
    1. J Clin Oncol. 2013 Apr 20;31(12):1592-605 - PubMed
    1. Nature. 2011 Nov 23;480(7377):387-90 - PubMed

Publication types

LinkOut - more resources

Feedback